An oral calcitonin gene-related peptide receptor antagonist for acute migraine management: Sign of a possible new chapter in headache medicine

2009 ◽  
Vol 9 (2) ◽  
pp. 91-93
Author(s):  
Ivan Garza
Medicine ◽  
2021 ◽  
Vol 100 (8) ◽  
pp. e24741
Author(s):  
Zizhen Zhang ◽  
Yunfeng Shu ◽  
Yun Diao ◽  
Yang Du ◽  
Lizhi Chen ◽  
...  

Author(s):  
S. Padmaja ◽  
J. Mohan

Migraine is a mysterious disorder characterized by pulsating head ache, which is actually characterized to one side and comes in attacks which will be lasting for about 3-48 hours and can be associated with nausea,vomiting,sensitivity to sound,flashes of light,vertigoand diarrhoea [1]. Most of the drugs which are in current use for actue migraine like triptans, treats the disorder symptomatically. A novel group of drugs has been in research for the migraine which treats the disorder pathologically. Calcitonin gene – related peptide (CGRP) has a major role in the pathophysiology of the disorder and hence CGRP receptor antagonist, known as Gepants are in the research process [2]. Gepants are being studied for the efficacy of treating acute migraine [2]. This article will be a review article about the drug – Ubrogepant, which is approved for treatment of migraine with acute attacks in adults [3].


2010 ◽  
Vol 333 (1) ◽  
pp. 152-160 ◽  
Author(s):  
Christopher A. Salvatore ◽  
Eric L. Moore ◽  
Amy Calamari ◽  
Jacquelynn J. Cook ◽  
Maria S. Michener ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document